{"DataElement":{"publicId":"3269794","version":"1","preferredName":"Biomarker Peroxisome Proliferative Activated Receptor Gamma Testing Occurrence Date","preferredDefinition":"Calendar date on which peroxisome proliferative activated receptor gamma (PPARy) testing is done and reported.","longName":"PPARY_TST_OCC_DT","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3269728","version":"1","preferredName":"Biomarker Peroxisome Proliferative Activated Receptor Gamma Testing Occurrence","preferredDefinition":"Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc_A procedure for critical evaluation; a means of determining the presence, quality, or truth of something._Expressed as multiple variants in adipose tissue (highest), skeletal muscle, spleen, heart, liver placenta, lung, and ovary by human PPARG Gene (NR1/PPAR Family), nuclear Peroxisome Proliferative Activated Receptor Gamma heterodimerizes with RXRs and NCOA6 coactivator to regulate target gene transcription. A receptor that binds peroxisome proliferators, such as hypolipidemic drugs and fatty acids, PPARG is a key regulator of adipocyte differentiation and glucose homeostasis. Once activated by ligand, PPARG binds to an acyl-CoA oxidase gene promoter element, activates transcription, and controls the peroxisomal fatty acid beta-oxidation pathway. Defects in PPARG can lead to type 2 insulin-resistant diabetes and hypertension. (NCI)_Occurrence; an instance of something happening.","longName":"BIOMK_PPARG_TST_OCC","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2969417","version":"1","preferredName":"Biomarker Peroxisome Proliferative Activated Receptor Gamma","preferredDefinition":"Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc:Expressed as multiple variants in adipose tissue (highest), skeletal muscle, spleen, heart, liver placenta, lung, and ovary by human PPARG Gene (NR1/PPAR Family), nuclear Peroxisome Proliferative Activated Receptor Gamma heterodimerizes with RXRs and NCOA6 coactivator to regulate target gene transcription. A receptor that binds peroxisome proliferators, such as hypolipidemic drugs and fatty acids, PPARG is a key regulator of adipocyte differentiation and glucose homeostasis. Once activated by ligand, PPARG binds to an acyl-CoA oxidase gene promoter element, activates transcription, and controls the peroxisomal fatty acid beta-oxidation pathway. Defects in PPARG can lead to type 2 insulin-resistant diabetes and hypertension. (NCI)","longName":"C16342:C34077","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biomarker","conceptCode":"C16342","definition":"A characteristic that can be objectively measured and serves as an indicator for normal biologic processes, pathogenic processes, state of health or disease, the risk for disease development and/or prognosis, or responsiveness to a particular therapeutic intervention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Peroxisome Proliferator-Activated Receptor Gamma","conceptCode":"C34077","definition":"Peroxisome proliferator-activated receptor gamma (505 aa, ~58 kDa) is encoded by the human PPARG gene. This protein plays a role in transcriptional regulation, lipid metabolism, cell differentiation, glucose homeostasis and apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7AC109C2-2FE5-5C6A-E040-BB89AD4314B5","latestVersionIndicator":"Yes","beginDate":"2009-12-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-15","modifiedBy":"ONEDATA","dateModified":"2009-12-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3269726","version":"1","preferredName":"Testing Occurrence","preferredDefinition":"A procedure for critical evaluation.:Occurrence; an instance of something happening.","longName":"C15336:C25275","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Testing","conceptCode":"C15336","definition":"A procedure for critical evaluation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Occurrence","conceptCode":"C25275","definition":"An instance of something happening, such as an event or incident.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC46B303-3F53-EC24-E040-BB89AD431A2A","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-06","modifiedBy":"ONEDATA","dateModified":"2011-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC46B303-3F64-EC24-E040-BB89AD431A2A","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-06","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2017121","version":"1","preferredName":"CTMS Date","preferredDefinition":"Date as required for Clinical Trials Monitoring Service submissions.  Exchange format is YYYYMMDD.  Display format is DDMMMYYYY, with the month display the first three letters of each month (Jan, Feb, Mar, etc.).","longName":"CTMS_DT","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"DATE","minLength":"4","maxLength":"8","minValue":null,"maxValue":null,"decimalPlace":null,"format":"DD/MON/YYYY","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008561","version":"1","preferredName":"Occurrences","preferredDefinition":"dates, times, and durations.","longName":"OCURS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B53BD1AB-090B-398B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-01-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2233081","version":"1","preferredName":"Date","preferredDefinition":"a particular day specified as the time something has, or will, happen.","longName":"C25164","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Date","conceptCode":"C25164","definition":"The particular day, month and year an event has happened or will happen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F90B5E56-BB15-0F45-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-09","modifiedBy":"ONEDATA","dateModified":"2005-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"A6545B3B-0FC3-40BF-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-07-21","endDate":null,"createdBy":"JASUR","dateCreated":"2002-07-21","modifiedBy":"HARTLEYG","dateModified":"2018-06-06","changeDescription":"8/30/17 jk Transferred context, added CSI and reg status, released per Round 5 finalization task. --- Display and exchange formats are based on CTMS reporting requirements v.3.02 and all subsequent versions of these guidelines.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2812571","version":"1","longName":"Lombardi Cancer Center","context":"NCIP"},{"publicId":"2812605","version":"1","longName":"Lombardi New CDEs","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"If Yes, Date of result report","type":"Preferred Question Text","description":"If Yes, Date of result reported","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AC46B303-3FB3-EC24-E040-BB89AD431A2A","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-06","modifiedBy":"REEVESD","dateModified":"2015-05-19","changeDescription":"Curated to support Lombardi Cancer Center clinical trial","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}